검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Denosumab |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Giant Cell Tumor of Bone |
Overview Indication | Postmenopausal Osteoporosis |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | targeting RANKL (denosumab), pro-inflammatory cytokines (IL-17 inhibitors), and Wnt pathway |
MoA Biomarker | Biomarkers, and Emerging Therapies |
PK/PD Half-life | 25.4 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Update on Glucocorticoid-Induced Osteoporosis: Emerging Therapeutic Strategies.. Glucocorticoids are widely prescribed for inflammatory diseases, but their adverse skeletal effects, particularly osteoporosis and fracture, remain clinically important. Glucocorticoid-induced osteoporosis (GIOP) is characterized by rapid disruption of bone remodeling, with an early increase in bone resorption followe… |
Clinical Primary efficacy | ORR 16.7% |
Clinical ORR | 16.7% |
Clinical Result source | ClinicalTrials.gov NCT04907851 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Denosumab |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Giant Cell Tumor of Bone |
Overview Indication | Postmenopausal Osteoporosis |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | targeting RANKL (denosumab), pro-inflammatory cytokines (IL-17 inhibitors), and Wnt pathway |
MoA Biomarker | Biomarkers, and Emerging Therapies |
PK/PD Half-life | 25.4 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Update on Glucocorticoid-Induced Osteoporosis: Emerging Therapeutic Strategies.. Glucocorticoids are widely prescribed for inflammatory diseases, but their adverse skeletal effects, particularly osteoporosis and fracture, remain clinically important. Glucocorticoid-induced osteoporosis (GIOP) is characterized by rapid disruption of bone remodeling, with an early increase in bone resorption followe… |
Clinical Primary efficacy | ORR 16.7% |
Clinical ORR | 16.7% |
Clinical Result source | ClinicalTrials.gov NCT04907851 |
Clinical Data Tier / Score | A · 44 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교